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Clinical PerspectiveWhat Is New?Impaired kidney function, assessed through estimated glomerular filtration rate for cystatin C and albumin‐to‐creatinine ratio, is associated with higher volumes of calcification in the coronary arteries, the aortic arch, and the extra‐ and intracranial internal carotid arteries, but this association is partly explained by the presence of traditional cardiovascular risk factors.There was no evidence for a mediating role for arterial calcification in the association between kidney function and cardiovascular events beyond traditional cardiovascular risk factors.What Are the Clinical Implications?In the general population with mild‐to‐moderate kidney impairment, a substantial portion of the association between worse kidney function and arterial calcification is explained by cardiovascular risk factors.Hence, these findings emphasize the need for novel investigations into other mechanisms underlying the increased risk of cardiovascular events in these individuals.

Introduction {#jah34025-sec-0008}
============

Impaired kidney function is accompanied by a higher risk of cardiovascular events, such as myocardial infarctions and stroke.[1](#jah34025-bib-0001){ref-type="ref"} One of the potential factors that can explain this excess risk is arterial calcification,[2](#jah34025-bib-0002){ref-type="ref"} which seems to be more prevalent in arteries of patients with chronic kidney disease compared with healthy individuals.[2](#jah34025-bib-0002){ref-type="ref"}, [3](#jah34025-bib-0003){ref-type="ref"}

Arterial calcification is one of the strongest risk factors for cardiovascular events and mortality.[4](#jah34025-bib-0004){ref-type="ref"} The calcification burden differs considerably across different vessel beds and carries differential predictive value for various manifestations of cardiovascular events.[5](#jah34025-bib-0005){ref-type="ref"}, [6](#jah34025-bib-0006){ref-type="ref"}, [7](#jah34025-bib-0007){ref-type="ref"}, [8](#jah34025-bib-0008){ref-type="ref"} Hence, it is important to understand whether the association of impaired kidney function with various forms of cardiovascular disease is through arterial calcification in the relevant (or adjunct) vessels.[6](#jah34025-bib-0006){ref-type="ref"}, [7](#jah34025-bib-0007){ref-type="ref"}, [8](#jah34025-bib-0008){ref-type="ref"}, [9](#jah34025-bib-0009){ref-type="ref"}

In a large study of community‐dwelling middle‐aged and elderly people, we investigated the association between kidney function and arterial calcification in 4 major vessel beds, including coronary artery, aortic arch, and extracranial and intracranial carotid artery calcification. We also studied the incidence of cardiovascular disease in subgroups of participants based on their kidney function level and calcification burden. Finally, we conducted a mediation analysis to evaluate whether arterial calcification mediates the association between impaired kidney function and higher incidence of cardiovascular disease.

Methods {#jah34025-sec-0009}
=======

Study Population {#jah34025-sec-0010}
----------------

The present study is embedded within the Rotterdam Study, a prospective population‐based study among individuals 45 years and older living in Ommoord, a district of Rotterdam. Between 2003 and 2006, all participants who visited the research center were invited to undergo nonenhanced multidetector computed tomography. In total, 2524 individuals were scanned (response rate 78%). Among them, 2241 participants had serum creatinine measurements, 2195 serum cystatin C, and 1767 urinary albumin‐to‐creatinine ratio.[10](#jah34025-bib-0010){ref-type="ref"} The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272‐159521‐PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; [www.trialregister.nl](http://www.trialregister.nl)) and into the World Health Organization International Clinical Trials Registry Platform (ICTRP; [www.who.int/ictrp/network/primary/en/](http://www.who.int/ictrp/network/primary/en/)) under shared catalogue number NTR6831.[10](#jah34025-bib-0010){ref-type="ref"} All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. Requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to Department of Epidemiology, Erasmus MC University Medical Center at <f.vanrooij@erasmusmc.nl>.

Assessment of Kidney Function Markers {#jah34025-sec-0011}
-------------------------------------

Serum creatinine was measured with an enzymatic assay method and standardized to isotope--dilution mass spectrometry--traceable measurements.[11](#jah34025-bib-0011){ref-type="ref"} Serum cystatin C was measured with a particle‐enhanced immunonephelometric assay.[12](#jah34025-bib-0012){ref-type="ref"} Estimated glomerular filtration rate (eGFR) was calculated for creatinine (eGFRcr) and cystatin C (eGFRcys) on the basis of the Chronic Kidney Disease Epidemiology Collaboration equation.[13](#jah34025-bib-0013){ref-type="ref"} Participants collected the first morning urine before arriving at the research center. Urine albumin and creatinine were determined by a turbidimetric method and measured by a Hitachi MODULAR P Analyzer (Roche/Hitachi Diagnostics, Mannheim, Germany). Albumin‐to‐creatinine ratio (milligrams per gram) was estimated by dividing albumin by creatinine. We used log‐transformed values to obtain values per doubling of the albumin‐to‐creatinine ratio. Before transformation, we added 1 to the values to account for those who did not have albuminuria. On average, there was a 6‐ and 5‐year difference between the time of computed tomography (CT) scans and eGFR and albumin‐to‐creatinine ratio measurements, respectively. Hence, all analyses were adjusted for the time interval between kidney function measurement and the time of the CT scans.

Assessment of Arterial Calcification {#jah34025-sec-0012}
------------------------------------

Noncontrast CT images were obtained using 16‐slice (n=785) or 64‐slice (n=1739) multidetector CT scanners (Somatom Sensation 16 or 64; Siemens, Forchheim, Germany). The acquisition‐protocol has been described in detail before.[5](#jah34025-bib-0005){ref-type="ref"}, [6](#jah34025-bib-0006){ref-type="ref"}, [7](#jah34025-bib-0007){ref-type="ref"} In short, using a cardiac scan and a scan that reached from the aortic arch to the intracranial vasculature (1 cm above the sella turcica), we scanned the following vessels: coronary arteries, aortic arch, extracranial carotid arteries, and intracranial carotid arteries. We visualized and quantified the amount of arterial calcification in these vessel beds. Coronary artery calcification, aortic arch calcification, and extracranial carotid artery calcification were quantified using commercially available software (Syngo CalciumScoring; Siemens). Intracranial carotid artery calcification was evaluated using a semiautomatic scoring method that is described in detail elsewhere (Figure [1](#jah34025-fig-0001){ref-type="fig"}).[5](#jah34025-bib-0005){ref-type="ref"} All calcification volumes are expressed in cubic millimeters. Because calcification scores were not normally distributed, we used natural log‐transformed values after adding 1 mm^3^ to the nontransformed values to account for zero values. To correct for the size of the vessels and be able to compare the effect estimates, we used standardized values of log‐transformed calcification scores.

![Visual representations of the vascular beds under study. AAC indicates aortic arch calcification; CAC, coronary artery calcification; ECAC, extracranial carotid artery calcification; ICAC, intracranial carotid artery calcification.](JAH3-8-e010930-g001){#jah34025-fig-0001}

Other Measurements {#jah34025-sec-0013}
------------------

All covariables were assessed at the time of kidney function measurements.[10](#jah34025-bib-0010){ref-type="ref"} Body mass index was calculated by dividing participants' weight in kilograms by the square of one\'s height in meters. Blood pressure was measured twice in a single visit and the average of 2 measurements was used in the analyses. Information on antihypertensive medication use was based on home interview. Serum total and high‐density lipoprotein cholesterol levels were measured using an automated enzymatic method. Diabetes mellitus was ascertained using general practitioners' records (including laboratory glucose measurements), hospital discharge letters, and serum glucose measurements from the Rotterdam Study visits, which take place approximately every 4 years. Information on smoking was gathered using questionnaires.

Incidence of Cardiovascular Events {#jah34025-sec-0014}
----------------------------------

Cardiovascular events included fatal or nonfatal acute myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, and stroke. Information on incident cases was obtained from general practitioners and from letters and discharge reports of medical specialists. Follow‐up data until January 1, 2012 were used (median follow‐up=5.5 years). All participants with a history of cardiovascular events at time of CT scanning were excluded from the analyses involving incidence of cardiovascular events.

Statistical Analysis {#jah34025-sec-0015}
--------------------

Associations between kidney function markers and arterial calcification in the 4 vessel beds were evaluated using linear regression models. Betas and 95% CIs for difference in arterial calcification volume were estimated per SD decrease of eGFR measures and doubling of albumin‐to‐creatinine ratio. We performed analyses in 2 models. In the first model, analyses were adjusted for age, sex, and cohort. In the second model, we additionally adjusted for cardiovascular risk factors including body mass index, hypertension, diabetes mellitus, smoking, total cholesterol, and high‐density lipoprotein cholesterol. To investigate a possible nonlinear association between kidney function markers and arterial calcification, we applied ordinary least squares linear regression models with restricted cubic splines with 3 knots at the 10th, 50th, and 90th percentiles. Additionally, we also created standard multivariate linear regression models with a quadratic term to provide effect estimates for eGFRcr. Moreover, we adjusted the associations of eGFRcr with arterial calcification for age (represented as spline) and interactions of age (as a spline) and sex. Since nonlinear associations with eGFRcr could be reflective of non‐GFR determinants, such as loss of muscle mass, we used eGFRcys for later analyses. We further compared the incidence rates of cardiovascular disease per 1000 person‐years in different categories of kidney function (based on eGFRcys) and arterial calcification.[14](#jah34025-bib-0014){ref-type="ref"} We used the globally accepted cutoff of 60 mL/min per 1.73 m^2^ for eGFR to define CKD.[15](#jah34025-bib-0015){ref-type="ref"}, [16](#jah34025-bib-0016){ref-type="ref"} Next, the categories were defined as (1) eGFRcys \>60 mL/min per 1.73 m^2^ and no calcification, (2) presence of either eGFRcys \<60 mL/min per 1.73 m^2^ or calcification, and (3) eGFRcys \<60 mL/min per 1.73 m^2^ and presence of calcification. For this analysis, we excluded those with previous history of cardiovascular disease (sample size=2091). We conducted a mediation analysis using the approach developed by Valeri and Van der Weele.[17](#jah34025-bib-0017){ref-type="ref"}, [18](#jah34025-bib-0018){ref-type="ref"} We presented total effect as well as natural direct effect (exposure effect that is not mediated by the mediator) and natural indirect effect (exposure effect that is mediated by the mediator). To explore the presence of interaction between worse kidney function and arterial calcification, we also evaluated all models after including an interaction term between kidney measures and volumes of arterial calcification.

Results {#jah34025-sec-0016}
=======

Table [1](#jah34025-tbl-0001){ref-type="table"} presents the characteristics of the study participants at the time of kidney function measurement. Mean age of the population was 69.5±6.7 years and 52% were female. Eighty percent of the population had an eGFRcys that was \>60 mL/min per 1.73 m^2^; in 10% this was between 45 and 60 mL/min per 1.73 m^2^, and in 2% the eGFRcys was \<45 mL/min per 1.73 m^2^. The associations between markers of kidney function and calcification in different vascular beds are presented in Table [2](#jah34025-tbl-0002){ref-type="table"}. In the age‐ and sex‐adjusted models, lower eGFRcys was associated with larger volumes of aortic arch calcification (difference in Ln‐transformed calcification volume per 1 SD lower eGFRcys: 0.07, 95% CI: 0.02, 0.12), extracranial carotid artery calcification (difference: 0.05, 95% CI: 0.01, 0.09), and intracranial carotid artery calcification (difference: 0.06, 95% CI: 0.02, 0.11). A higher albumin‐to‐creatinine ratio was associated with larger volumes of coronary artery calcification (difference in Ln‐transformed calcification volume per doubling of albumin‐to‐creatinine ratio: 0.06, 95% CI: 0.04, 0.09), aortic arch calcification (difference: 0.05, 95% CI: 0.02, 0.08), extracranial carotid artery calcification (difference: 0.04, 95% CI: 0.01, 0.07), and intracranial carotid artery calcification (difference: 0.05, 95% CI: 0.02, 0.07). After adjustment for cardiovascular risk factors, the effect estimates attenuated and were no longer statistically significant for eGFR. The association between albumin--creatinine ratio and calcification in coronary artery calcification and aortic arch calcification remained statistically significant (Table [2](#jah34025-tbl-0002){ref-type="table"}). We noted a U‐shaped association between eGFRcr and calcification in all 4 vascular beds (all *P*\<0.05) (Figure [2](#jah34025-fig-0002){ref-type="fig"} and Figure [S1](#jah34025-sup-0001){ref-type="supplementary-material"}; results from standard linear regression models including the quadratic term are shown in Table [S1](#jah34025-sup-0001){ref-type="supplementary-material"}). Figure [S2](#jah34025-sup-0001){ref-type="supplementary-material"} compares the model including eGFRcr as nonlinear term and the model using both eGFRcr and covariables as spline.

###### 

Baseline Characteristics of Study Participants

  -------------------------------------------------- ---------------------
  Sample size, n                                     2241
  Age, y                                             69.5 (6.7)
  Women                                              1163 (51.9)
  Systolic blood pressure, mm Hg                     141.7 (20.8)
  Diastolic blood pressure, mm Hg                    78.3 (10.8)
  Body mass index, kg/m^2^                           26.9 (3.7)
  Current smoking                                    402 (18.0)
  Total cholesterol, mmol/L                          5.8 (0.9)
  HDL cholesterol, mmol/L                            1.4 (0.4)
  Hypertension                                       1334 (59.5)
  Diabetes mellitus                                  214 (9.5)
  eGFR creatinine, mL/min per 1.73 m^2^              79.3 (13.8)
  eGFR cystatin C, mL/min per 1.73 m^2^              80.2 (17.0)
  Albumin‐to‐creatinine ratio, mg/g                  4.5 (2.4--10.4)
  Coronary artery calcification, mm^3^               52.1 (1.8--271.4)
  Aortic arch calcification, mm^3^                   250.7 (42.8--827.2)
  Extracranial carotid artery calcification, mm^3^   22.5 (0--113.6)
  Intracranial carotid artery calcification, mm^3^   42.3 (6.7--140.5)
  -------------------------------------------------- ---------------------

Categorical variables are presented as numbers (percentages), continuous variables as means (SD), and albumin‐to‐creatinine ratio and calcification markers are presented as medians (interquartile ranges). The following variables had missing data: body mass index (n=7), systolic and diastolic blood pressure (n=5), hypertension (n=12), smoking (n=9), and history of diabetes mellitus (n=9). eGFR indicates estimated glomerular filtration rate; HDL, high‐density lipoprotein.

###### 

Association Between Kidney Function and Calcification in Major Arteries

                                                            CAC                  AAC     ECAC                 ICAC                                                      
  --------------------------------------------------------- -------------------- ------- -------------------- ------- -------------------- ------- -------------------- -------
  eGFRcys (n=2195)[a](#jah34025-note-0004){ref-type="fn"}                                                                                                               
  Model 1                                                   0.04 (−0.01, 0.08)   0.086   0.07 (0.02, 0.12)    0.003   0.05 (0.01, 0.09)    0.040   0.06 (0.02, 0.11)    0.009
  Model 2                                                   0.01 (−0.03, 0.05)   0.663   0.04 (−0.00, 0.09)   0.062   0.03 (−0.02, 0.08)   0.195   0.04 (−0.01, 0.09)   0.078
  ACR (n=1767)[a](#jah34025-note-0004){ref-type="fn"}                                                                                                                   
  Model 1                                                   0.06 (0.04, 0.09)    0.001   0.05 (0.02, 0.08)    0.001   0.04 (0.01, 0.07)    0.012   0.05 (0.02, 0.07)    0.002
  Model 2                                                   0.04 (0.01, 0.07)    0.004   0.03 (0.01, 0.06)    0.042   0.02 (−0.01, 0.05)   0.214   0.03 (−0.00, 0.06)   0.063

Model 1: Adjusted for age, sex, and cohort effect. Model 2: Adjusted for model 1 and additionally for body mass index, hypertension, diabetes mellitus, smoking, total cholesterol, and HDL cholesterol. AAC indicates aortic arch calcification; ACR, albumin‐to‐creatinine ratio; CAC, coronary artery calcification; ECAC, extracranial carotid artery calcification; eGFR, estimated glomerular filtration rate; eGFRcys, eGFR calculated for creatinine; HDL, high‐density lipoprotein; ICAC, intracranial carotid artery calcification.

Reported beta and CIs are standardized log increase in calcification per 1 SD decrease in eGFR estimates or doubling in ACR.

![Nonlinear association of eGFR based on creatinine and arterial calcification in different vascular beds. *X*‐axes represent eGFR values based on creatinine and *Y*‐axes represent logarithm of arterial calcification values. AAC indicates aortic arch calcification; CAC, coronary artery calcification; ECAC, extracranial carotid artery calcification; eGFR, estimated glomerular filtration rate; ICAC, intracranial carotid artery calcification.](JAH3-8-e010930-g002){#jah34025-fig-0002}

Participants with both eGFRcys \<60 mL/min per 1.73 m^2^ and calcification in their vascular beds had higher incidence of cardiovascular disease compared with individuals with eGFRcys \>60 and without calcification (all *P*\<0.05) (Figure [3](#jah34025-fig-0003){ref-type="fig"}).

![Incidence rates of cardiovascular disorders in 3 categories of participants based on eGFR level and presence of calcification. AAC indicates aortic arch calcification; CAC, coronary artery calcification; CVD, cardiovascular disease; ECAC, extracranial carotid artery calcification; eGFR, estimated glomerular filtration rate; ICAC, intracranial carotid artery calcification.](JAH3-8-e010930-g003){#jah34025-fig-0003}

Table [3](#jah34025-tbl-0003){ref-type="table"} presents the results of the mediation analysis. Adjusted for age, sex, and cardiovascular risk factors, percent mediated via arterial calcification in the observed association between kidney function measures and incident cardiovascular disease was small and not statistically significant (from 0% to 23%). Including an interaction term between kidney measures and volumes of arterial calcification did not statistically significantly improve the models (data not shown).

###### 

Estimates of Direct and Indirect Effects of Kidney Function Measures on Cardiovascular Disease and Percentage Mediated by Arterial Calcification

                             Cardiovascular Disease   Percent Mediated[a](#jah34025-note-0006){ref-type="fn"}                       
  -------------------------- ------------------------ --------------------------------------------------------- ------------------- ----
  eGFR (per 1 SD decrease)                                                                                                          
  CAC                        1.19 (0.98, 1.44)        1.00 (0.98, 1.03)                                         1.20 (0.99, 1.45)   0
  AAC                        1.17 (0.97, 1.42)        1.01 (0.99, 1.03)                                         1.19 (0.99, 1.44)   6
  ECAC                       1.17 (0.97, 1.42)        1.01 (0.99, 1.03)                                         1.18 (0.98, 1.43)   6
  ICAC                       1.18 (0.97, 1.42)        1.02 (0.99, 1.04)                                         1.19 (0.99, 1.44)   11
  ACR (per doubling)                                                                                                                
  CAC                        1.07 (0.95, 1.21)        1.02 (1.00, 1.03)                                         1.09 (0.96, 1.23)   23
  AAC                        1.07 (0.95, 1.21)        1.01 (0.99, 1.02)                                         1.08 (0.96, 1.22)   13
  ECAC                       1.08 (0.96, 1.22)        1.00 (0.99, 1.01)                                         1.08 (0.96, 1.22)   0
  ICAC                       1.08 (0.95, 1.21)        1.01 (0.99, 1.03)                                         1.09 (0.97, 1.23)   12

Models are adjusted for age, sex, cohort effect and body mass index, hypertension, diabetes mellitus, smoking, total cholesterol, and HDL cholesterol. AAC indicates aortic arch calcification; ACR, albumin‐to‐creatinine ratio; CAC, coronary artery calcification; ECAC, extracranial carotid artery calcification; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; ICAC, intracranial carotid artery calcification.

The portion of the total effects mediated by arterial calcification is defined as the natural indirect effect over the total effect.

Discussion {#jah34025-sec-0017}
==========

In this population‐based study, we found that a lower eGFRcys and a higher albumin‐to‐creatinine ratio were associated with higher volumes of calcification in the coronary arteries, the aortic arch, and the extra‐ and intracranial internal carotid arteries. The order of magnitude of these associations was similar across all 4 vessels. The effect estimates attenuated after adjustment for cardiovascular risk factors. We observed a nonlinear association between eGFRcr and calcifications in all vessel beds. Adjusting for age, sex, and cardiovascular risk factors, arterial calcification did not mediate the association between kidney function and cardiovascular events.

Previous studies including kidney disease patients investigated the link between kidney function and calcification in the coronary arteries and the aorta.[19](#jah34025-bib-0019){ref-type="ref"}, [20](#jah34025-bib-0020){ref-type="ref"}, [21](#jah34025-bib-0021){ref-type="ref"}, [22](#jah34025-bib-0022){ref-type="ref"}, [23](#jah34025-bib-0023){ref-type="ref"}, [24](#jah34025-bib-0024){ref-type="ref"}, [25](#jah34025-bib-0025){ref-type="ref"} Kidney impairment has been associated with coronary calcification in different populations.[19](#jah34025-bib-0019){ref-type="ref"}, [21](#jah34025-bib-0021){ref-type="ref"}, [23](#jah34025-bib-0023){ref-type="ref"}, [25](#jah34025-bib-0025){ref-type="ref"} Reports on patients with chronic kidney disease found an independent association between kidney function and vascular calcification,[19](#jah34025-bib-0019){ref-type="ref"}, [21](#jah34025-bib-0021){ref-type="ref"} whereas the association was not independent of traditional cardiovascular risk factors in the general population.[23](#jah34025-bib-0023){ref-type="ref"} Similarly, among predialysis patients, lower eGFR was found to be prominently related to the presence of abdominal aortic calcification.[20](#jah34025-bib-0020){ref-type="ref"} In contrast, a report from the population‐based Multi‐Ethnic Study of Atherosclerosis showed that mild impairment in kidney function is only modestly associated with aortic valve calcification.[24](#jah34025-bib-0024){ref-type="ref"} We observed that, similar to other population‐based studies, the effect estimates attenuated after adjustment for cardiovascular risk factors, suggesting that in the general population at least part of this association is explained by cardiovascular risk factors. Vascular calcification can be the consequence of a wide range of different biological processes. In patients with more severe stages of kidney disease, mechanisms directly related to lower glomerular filtration, such as disturbed calcium--phosphate metabolism, or medical therapies to treat renal osteodystrophy, have also been implicated in the pathophysiology of vascular calcification.[2](#jah34025-bib-0002){ref-type="ref"}, [3](#jah34025-bib-0003){ref-type="ref"}, [26](#jah34025-bib-0026){ref-type="ref"} This could explain the association between kidney function markers and calcification independent of cardiovascular risk factors in a population with more advanced stages of kidney impairment. Future studies investigating this association in populations with lower levels of eGFR are needed to explore mechanisms beyond cardiovascular risk factors.

The present study extends the literature by including calcification in vessels other than the coronary arteries or the aorta. Calcification can have different anatomical and histological locations. Given that correlations between calcifications in different vessel beds are only moderate[27](#jah34025-bib-0027){ref-type="ref"}, [28](#jah34025-bib-0028){ref-type="ref"} (*r* from our study=0.4--0.5), the association between kidney function and calcification could differ across various vessel beds with potential implications for clinical events. For example, calcification in intra‐ and extracranial arteries has been shown be a strong predictor of stroke.[5](#jah34025-bib-0005){ref-type="ref"}, [7](#jah34025-bib-0007){ref-type="ref"} Patients with kidney impairment also have excess risk for stroke and one of the proposed mechanisms is a higher load of arterial calcification in these patients.[29](#jah34025-bib-0029){ref-type="ref"} Similar to coronary and aortic calcification, we observed a trend showing an association between eGFR and albuminuria with calcification in intracranial carotid arteries. The strength of the association as well as the incidence rate of cardiovascular disorders were similar across different vessels, suggesting that the association between kidney function and arterial calcification is not restricted to a particular type of a vessel or region but rather a more systemic phenomenon. We found that, in adjusted models, a small portion of the association between kidney measures and cardiovascular events was mediated through arterial calcification and were not statistically significant. Our population‐based cohort is relatively healthy with lower burden of calcification, and the mediating role of calcification is likely more prominent in patients with advanced chronic kidney disease.

We noted a nonlinear association between creatinine‐based eGFR and calcification. Nonlinear associations of creatinine in relation to cardiovascular outcomes have been reported previously.[12](#jah34025-bib-0012){ref-type="ref"}, [30](#jah34025-bib-0030){ref-type="ref"} Individuals with very low creatinine levels (high eGFR) are also at increased risk of cardiovascular disorders, possibly because of malnutrition and loss of muscle mass.[31](#jah34025-bib-0031){ref-type="ref"} Unlike creatinine, levels of serum cystatin C are reported to be independent of muscle mass.[31](#jah34025-bib-0031){ref-type="ref"} Nevertheless, inflammation and cardiovascular risk factors such as obesity and diabetes mellitus can also influence serum cystatin C levels.[31](#jah34025-bib-0031){ref-type="ref"}, [32](#jah34025-bib-0032){ref-type="ref"} Another reason for the nonlinear association of eGFRcr and calcification could be because of the glomerular hyperfiltration. Hyperfiltration has been associated with vascular dysfunction because it may represent an adaptive mechanism to maintain glomerular perfusion.[33](#jah34025-bib-0033){ref-type="ref"}, [34](#jah34025-bib-0034){ref-type="ref"} Given that the same trend was not observed with eGFR based on cystatin C, this observation should be confirmed in future studies. We found more prominent associations when using albuminuria as a marker of kidney function than when using eGFR. This finding has been reported in different studies, with albuminuria being a marker of generalized endothelial dysfunction as the most appealing explanation.[35](#jah34025-bib-0035){ref-type="ref"}, [36](#jah34025-bib-0036){ref-type="ref"} In addition, albuminuria may better capture the influence of other calcifying mechanisms such as inflammation in the arterial system.[37](#jah34025-bib-0037){ref-type="ref"}

We included a relatively large sample of community‐dwelling individuals with available standardized image‐based measures of calcification in 4 major vascular beds, and different markers of kidney function that enabled 1‐on‐1 comparisons of kidney function measures and arterial calcification in different vessel beds within this population. However, limitations of our study should be acknowledged. Given the relatively preserved eGFR in our population, the findings are difficult to extrapolate to older individuals and people with more severe kidney disease. One of the main assumptions of mediation analysis is to rule out confounding; we adjusted the analyses for main cardiovascular risk factors and demographic characteristics but there is the possibility of residual confounding and reverse causation. One important potential confounder that we did not take into account is the level of serum phosphate. Serum phosphate has been found to be an independent risk factor for cardiovascular events in both the general population and in patients with kidney disease. Future studies are needed to study the role of phosphate in this association. Another important limitation of this study is the time interval between measuring kidney function and CT scan. Although adjustment for the time interval did not change the results, we acknowledge that during this interval there may have been changes in kidney function measures.

In conclusion, we found that in the general population, impairment of kidney function, particularly albumin‐to‐creatinine ratio, is associated with larger volumes of arterial calcification in different major vascular beds. At least part of this association is explained by cardiovascular risk factors. The effect estimates did not seem to be more prominent with 1 vessel bed and was rather similar across all 4 vessels. Arterial calcification did not mediate the association between kidney function and cardiovascular disease above cardiovascular risk factors in the general population.
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**Table S1.** The Association Between GFRcr/GFRcr Squared and Calcification in Different Arteries

**Figure S1.** Nonlinear association of kidney measures and arterial calcification in different vascular beds.

**Figure S2.** Nonlinear association of eGFRcr and arterial calcification in different vascular beds.
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